Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

od of 2008 was primarily a result of the 2008 write-off of $1.9 million of deferred offering costs related to a delay in the Company's IPO. Also, in the 2009 period there were decreases in contract service costs associated with several of Omeros' clinical and preclinical programs and in clinical trial expenses due to the prior completion of enrollment in the Company's Phase 2 clinical study of OMS103HP for arthroscopic meniscectomy surgery.

Total operating expenses for the nine months ended September 30, 2009 were $16.5 million, compared to $19.1 million for the same period in 2008. The decrease in operating expenses in the nine months ended September 30, 2009 as compared to the same period of 2008 was primarily a result of items noted above.

Recent Highlights

  • Priced the Company's IPO on October 7, 2009, receiving net proceeds of approximately $61.8 million, and began trading on The NASDAQ Global Market under the ticker symbol "OMER" on October 8, 2009.
  • Announced positive results from the Phase 1/Phase 2 clinical trial of OMS302, Omeros' PharmacoSurgery product candidate being developed for use during ophthalmological procedures. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles. The Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of OMS302 added to a standard surgical irrigation solution. Data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control.
  • Amended its agreement with Patobios Limited by which Omeros has the exclusive right to acquire
    '/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... 30, 2014 Award winning unified ... announces four new-hosted collaboration bundles that combine next ... quality conferencing experiences for low, flat rate fees. ... from, businesses have optimized solutions to meet their ... include audio only minutes (1K, 5K, 10K increments) ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Metformin on Insulin Sensitization Poster Wins One ... ... Seahorse Bioscience, Inc.,leaders in real-time measurement of cellular bioenergetics announced today,the ... award at the 16th European Congress on Obesity (ECO 2008) May ...
... Include Clinical Trial Updates, BETHESDA, Md., July ... OTC Bulletin Board: NWBO), (the,"Company or NWBT"), today ... Chief Executive Officer, will deliver a presentation updating,the ... for the,treatment of cancer, at the "Next Generation ...
... ARGONNE, Ill. (July 17, 2008) Researchers at the U.S. ... industrial partners have won two R&D 100 Awards for ... scientists have been awarded 101 R&D 100 Awards since ... a prestigious R&D 100 Award -- dubbed the "Oscars ...
Cached Biology Technology:Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity 2Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Leadership Strengthened with Clinical ... Standards-Based Data Management, WHIPPANY, N.J. and ATLANTA, ... it agreed to terms to acquire Zurich,Biostatistics, Inc. ... regulatory submissions, the acquisition further strengthens,ISI,s Clinical Data ...
... SHORES, Calif., Sept. 10 ,Communication Intelligence Corporation (OTC ... signature solutions for business process,automation in the financial ... announced today the appointment of Michael Betts to,the ... over 30 years of experience in the insurance ...
... J. Michael McConnell, Director of,National Intelligence and ... Intelligence will provide valuable insights into the intelligence,challenges ... the United States,Intelligence Community 100 Day Plan for ... The Office of the Director of National Intelligence ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3